New antibiotic combo tested for lung penetration in healthy volunteers
NCT ID NCT06916156
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested whether a combination of two antibiotics, ANT3310 and meropenem, can reach the fluid lining the lungs after being given through an IV. Twenty-six healthy adults received three doses over 24 hours, and a lung wash (bronchoscopy) was used to measure drug levels. The goal was to understand how much of the drug gets into the lungs, which is important for treating serious lung infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ANT3310 and meropenem (antibiotic combination)
- What this could lead to
- If successful, this could help design better dosing for lung infections, potentially improving treatment of serious bacterial pneumonia.
- What could go wrong
- This is a very early Phase 1 study in only 26 healthy volunteers, not patients. It only measures drug levels, not whether the combination actually fights infection. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS STUDY ON HEALTHY VOLUNTEERS ADULTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pulmonary Associates, PA
Phoenix, Arizona, 85032, United States